专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09682109B2 Antiviral resistance mutants and applications thereof 有权
公开(公告)号：US09682109B2
公开(公告)日：2017-06-20
申请号：US11913106
申请日：2006-10-20
申请人： Angeline Ingrid Bartholomeusz , Stephen Locarnini , Anna Ayres , Margaret Littlejohn , Peter William Angus
发明人： Angeline Ingrid Bartholomeusz , Stephen Locarnini , Anna Ayres , Margaret Littlejohn , Peter William Angus
IPC分类号： C12Q1/68 , C12N15/117 , A61P31/20 , A61K35/76 , C12N7/00 , C12Q1/18
CPC分类号： A61K35/76 , C12N7/00 , C12N2730/10132 , C12Q1/18
摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to agents such as nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.

2. 发明申请

US20080274083A1 Antiviral Resistance Mutants and Applications Thereof 有权
标题翻译：抗病毒抗性突变体及其应用
公开(公告)号：US20080274083A1
公开(公告)日：2008-11-06
申请号：US11913106
申请日：2006-10-20
申请人： Angeline Ingrid Bartholomeusz , Stephen Locarnini , Anna Ayres , Margaret Littlejohn , Peter William Angus
发明人： Angeline Ingrid Bartholomeusz , Stephen Locarnini , Anna Ayres , Margaret Littlejohn , Peter William Angus
IPC分类号： A61K35/76 , C12N7/01 , A61P31/12 , C12Q1/70
CPC分类号： A61K35/76 , C12N7/00 , C12N2730/10132 , C12Q1/18
摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to agents such as nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
摘要翻译：本发明一般涉及对药剂例如核苷或核苷酸类似物或其它DNA聚合酶拮抗剂的敏感性降低和/或与免疫试剂降低的相互作用的病毒变体。更具体地，本发明涉及对核苷或核苷酸类似物或其它DNA聚合酶拮抗剂表现出完全或部分抗性和/或降低与病毒表面成分抗体的相互作用的乙型肝炎病毒（HBV）变体，包括对这些抗体的敏感性降低。本发明进一步考虑了用于检测此类病毒变体的测定法，该测定法可用于监测抗病毒治疗方案和开发针对病毒剂，特别是HBV变体的新的或修饰的疫苗。本发明还考虑使用病毒变体来筛选和/或开发或设计能够抑制病毒感染，复制和/或释放的试剂。

3. 发明公开

US20240123025A1 LIPOPEPTIDES FOR USE IN TREATING LIVER DISEASES AND CARDIOVASCULAR DISEASES 审中-公开
公开(公告)号：US20240123025A1
公开(公告)日：2024-04-18
申请号：US18330135
申请日：2023-06-06
申请人： Volker Cleeves , RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
发明人： Volker Cleeves , Stephan Urban , Ralf Kubitz
IPC分类号： A61K38/16 , A61K31/00 , A61K31/575 , A61K38/17 , C07K14/005 , C07K14/705 , C12N7/00 , G01N33/50 , G01N33/68 , G01N33/92
CPC分类号： A61K38/162 , A61K31/00 , A61K31/575 , A61K38/1709 , C07K14/005 , C07K14/705 , C12N7/00 , G01N33/5023 , G01N33/5067 , G01N33/6893 , G01N33/92 , C12N2730/10122 , C12N2730/10132 , G01N2333/705 , G01N2500/04 , G01N2500/10 , G01N2800/085
摘要： The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease.

4. 发明授权

US5980901A Viral defective interfering particles and uses thereof 失效
标题翻译：病毒性干扰颗粒及其用途
公开(公告)号：US5980901A
公开(公告)日：1999-11-09
申请号：US933480
申请日：1997-09-18
申请人： Chiaho Shih , Ta-Tung Yuan
发明人： Chiaho Shih , Ta-Tung Yuan
IPC分类号： A61K35/76 , A61K39/00 , A61K39/29 , A61P31/12 , C07K14/02 , C12N7/00 , A61K39/12 , C12N7/04
CPC分类号： C07K14/005 , A61K39/12 , A61K39/292 , C12N7/00 , A61K39/00 , C12N2730/10122 , C12N2730/10132 , C12N2730/10134 , Y10S977/802 , Y10S977/805 , Y10S977/915 , Y10S977/918
摘要： The present invention provides a composition of matter comprising a defective interfering virus particle, wherein said particle naturally occurs in a human infection and wherein said particles has a naturally occurring core antigen internal deletion. Provided is a pharmaceutical composition, comprising defective interfering virus particle and a pharmaceutically acceptable carrier. Provided is a method for preparing defective interfering virus, comprising the steps of: (1) introduce a defective interfering virus and a complementing plasmid expressing a wild type virus core antigen and optionally containing a drug resistance gene, into a recipient cell; (2) selecting for stably transfected colonies; (3) growing the drug resistant cells and screening for the production of virus DNA replication; and (4) collecting defective interfering virus particles from the medium. Further provided is a vaccine, comprising a defective interfering virus particle.
摘要翻译：本发明提供了包含有缺陷的干扰性病毒颗粒的物质组合物，其中所述颗粒天然存在于人感染中，并且其中所述颗粒具有天然存在的核心抗原内部缺失。提供了一种药物组合物，其包含有缺陷的干扰性病毒颗粒和药学上可接受的载体。本发明提供一种制备有缺陷的干扰性病毒的方法，其特征在于包括以下步骤：（1）将受损细胞引入缺陷干扰病毒和表达野生型病毒核心抗原的互补质粒，并任选地含有耐药性基因; （2）选择稳定转染的菌落; （3）生长耐药细胞并筛选生产病毒DNA复制; 和（4）从介质中收集有缺陷的干扰性病毒颗粒。还提供了包含有缺陷的干扰性病毒颗粒的疫苗。

5. 发明申请

US20170112898A1 FORMULATIONS OF HEPALATIDE 审中-公开
公开(公告)号：US20170112898A1
公开(公告)日：2017-04-27
申请号：US14901249
申请日：2014-06-24
申请人： SHANGHAI HEP PHARMACEUTICAL CO., LTD.
发明人： Hongli Liu
IPC分类号： A61K38/16 , A61K47/26 , C12N7/00 , A61K47/02
CPC分类号： A61K38/162 , A61K9/0019 , A61K9/19 , A61K38/16 , A61K47/02 , A61K47/26 , C12N7/00 , C12N2730/10122 , C12N2730/10132
摘要： The present disclosure provides a drug formulation for hepalatide, comprising hepalatide and a buffer salt, and containing or not containing an osmotic regulator and/or an excipient.

6. 发明申请

US20160015775A1 Lipopeptides for Use in Treating Liver Diseases and Cardiovascular Diseases 审中-公开
标题翻译：用于治疗肝脏疾病和心血管疾病的脂肽
公开(公告)号：US20160015775A1
公开(公告)日：2016-01-21
申请号：US14442304
申请日：2013-11-12
申请人： Volker CLEEVES , RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
发明人： Volker CLEEVES , Stephan URBAN , Ralf KUBITZ
IPC分类号： A61K38/16 , G01N33/50 , C12N7/00 , C07K14/005
CPC分类号： A61K38/162 , A61K31/00 , A61K31/575 , A61K38/1709 , C07K14/005 , C07K14/705 , C12N7/00 , C12N2730/10122 , C12N2730/10132 , G01N33/5023 , G01N33/5067 , G01N33/6893 , G01N33/92 , G01N2333/705 , G01N2500/04 , G01N2500/10 , G01N2800/085 , A61K2300/00
摘要： The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease.
摘要翻译：本发明涉及用于诊断，预防和/或治疗肝脏疾病或病症，优选肝脏涉及代谢性疾病以及控制或改变胆固醇水平或胆固醇摄取的基于脂肽的化合物，从而诊断，预防和/或治疗心血管疾病。本发明还涉及用于测试或测量NTCP介导的测试化合物转运的体外或体内测定或方法。本发明还涉及一种用于诊断，预防和/或治疗肝脏疾病或病症的方法，包括向患者施用治疗有效量的基于脂肽的化合物。本发明还涉及用于诊断，预防和/或治疗心血管疾病的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式